The Chinese-German Journal of Clinical Oncology

, Volume 1, Issue 4, pp 230–232 | Cite as

Somatostatin enhances the antineoplastic effects of tamoxifen on breast carcinoma in vitro

  • Zeng Xizhi
  • Yao Zhenxiang
Original Articles



To study the antineoplastic effects of tamoxifen (TAM) in combination with a somatostatin analogue (octreotide, OCT) on breast cancer.


Estrogen receptor (ER)-positive (MCF-7) and ER-negative (MDA-MB-435S) human breast carcinoma cell lines were treated with TAM or OCT, or combination of both agentsin vitro. Cell proliferation was evaluated by MTT assay, distribution of cell cycle and rate of apoptosis were determined by flow cytometry.


The inhibitory effect of OCT or TAM on proliferation of MCF-7 cells was associated with cell arrest in G0/G1 phase and induction of apoptosis. The inhibitory effect on proliferation of MCF-7 cells was enhanced when treatment of TAM combined with OCT. The increased rate of apoptosis induced by combination of TAM and OCT was much higher than use of either TAM or OCT alone. TAM or OCT also had weak inhibitory effect on MDA-MB-435S cell. The cells were arrested at S phase by TAM and at G0/G1 phase by OCT, but the induction of apoptosis was not identified. However, the rate of apoptosis was 22.7% if combined treatment of TAM and OCT applied.


TAM and OCT can synergistically inhibit proliferation and induce apoptosis of ER-positive and ER-negative breast cancer cells. The synergism of TAM and OCT may be of interest in the clinical treatment of breast carcinoma.

Key words

breast neoplasms octreotide tamoxifen 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ercoli A, Scambia G, Comparative study on the indication of cytostasis and apoptosis by ICII82780 and tamoxifen in an estrogen receptor-negative ovarian cancer cell line. Int J Cancer, 1998, 76: 47–54.PubMedCrossRefGoogle Scholar
  2. 2.
    Xu Y, Song J, Berelowitz M,et al. Estrogen regulates somatostatin receptor subtype 2 messenger ribonucleic acid expression in human breast cancer cells. Endocrinology, 1996, 137: 5634–5640CrossRefGoogle Scholar
  3. 3.
    Evans AA, Crook T, Laws S,et al. Analysis of somatostatin receptor subtype mRNA expression in human breast cancer. Br J Cancer, 1997, 75: 797–803.Google Scholar
  4. 4.
    Thangaraju M, Sharma K, Liu D,et al. Interdependent regulation of intracellular acidification and SHP-1 in apoptosis. Cancer Res, 1999, 59: 1649–1654.PubMedGoogle Scholar
  5. 5.
    Zhang GJ, Kimijima I, Onda M,et al. Tamoxifen-induced apoptosis in breast cancer cells relates to down-regulation of Bcl-2, but not Bax and bcl-X(L), without alteration of p53 protein levels. Clin Cancer Res, 1999, 5: 2971–2977.PubMedGoogle Scholar
  6. 6.
    Sharma K, Srikant CB. Induction of wild-type p53, Bax, and acidic endonuclease during somatostatin-signaled apoptosis in MCF-7 human breast cancer cells. Int J Cancer, 1998, 76: 259–266.PubMedCrossRefGoogle Scholar
  7. 7.
    Shen F, Xue X, Weber G. Tamoxifen and genistein synergistically down-regulate signal transduction and proliferation in estrogen receptor-negative human breast carcinoma MDA-MB-435 cells. Anticancer Res, 1999, 19: 1657–1662.PubMedGoogle Scholar

Copyright information

© Springer 2002

Authors and Affiliations

  • Zeng Xizhi
    • 1
  • Yao Zhenxiang
    • 1
  1. 1.Department of General Surgery, First Affiliated Hospital of ChongqingUniversity of Medical SciencesChongqingChina

Personalised recommendations